A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Part of paid clinical trials in Fayetteville, North Carolina.
- Sponsor
- Dianthus Therapeutics
- Study ID
- NCT07647510
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Myasthenia Gravis, Generalized
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- Claseprubart — DRUGIV loading dose on Day 1
- Placebo — DRUGIV infusion on Day 1
- Claseprubart — COMBINATION_PRODUCTPrefilled syringe containing claseprubart for SC administration
- Placebo — COMBINATION_PRODUCTPrefilled syringe containing placebo for SC administration
Study Details
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
Key Dates
- First listed
- Jun 15, 2026
- Start date
- Jul 31, 2026
- Status verified
- Jun 2026
- Primary completion
- Dec 31, 2028
- Completion
- Sep 30, 2031
Study Design
- Enrollment
- 195 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: PlaceboIntravenous (IV) infusion of Placebo on Day 1 followed by subcutaneous (SC) injections of Placebo every 2 weeks (Q2W) starting at Week 1 (Day 8).
- Experimental: Claseprubart Q2WIV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart Q2W starting at Week 1 (Day 8).
- Experimental: Claseprubart Every 4 weeks (Q4W)IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart or Placebo Q2W starting at Week 1 (Day 8), with doses alternating between claseprubart and placebo.
Primary Outcome Measure
Change from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score [ Time Frame: Baseline (Day 1) to Week 17 ]
Central Contacts
- Dianthus Clinical Contact Center929-999-4055
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cinical Study Site | Fayetteville | North Carolina | 28304 | - |
Find similar trials in Fayetteville, NC
By research site
Related Studies
- Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation ResearchRecruiting · Brain Inflammation Collaborative · Delafield, Wisconsin
- Myasthenia Gravis Foundation of America Global MG Patient RegistryRecruiting · Myasthenia Gravis Foundation of America · Westborough, Massachusetts
- Multi-Modal Monitoring of Disease Symptoms in Myasthenia GravisNot Yet Recruiting · BioSensics · Boston, Massachusetts
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisPHASE2 · Recruiting · Vertex Pharmaceuticals Incorporated · Boca Raton, Florida